Medicine Overview

Indication
Know Medicine, Follow Guideline

Adult Dose
Clinical InformationAdministration Information
Indication: Differential diagnosis of supraventricular tachycardias
Age: Adult
Dose: Intravenous injection – 3 mg
Frequency: rapid intravenous injection into a central or large peripheral vein over 2 seconds with cardiac monitoring
Note: 6 mg may be given after 1-2 minutes if necessary, then 12 mg after a further 1-2 minutes. Avoid increments if high level atrioventricular block occurs at any particular dose.
Indication: Paroxysmal supraventricular tachycardia
Age: Adult
Dose: Intravenous injection – 3 mg
Frequency: rapid intravenous injection into a central or large peripheral vein over 2 seconds with cardiac monitoring
Note: 6 mg may be given after 1-2 minutes if necessary, then 12 mg after a further 1-2 minutes. Avoid increments if high level atrioventricular block occurs at any particular dose.

Child Dose
Clinical InformationAdministration Information
Indication: Differential diagnosis of supraventricular tachycardias
Age: Child
Dose: Intravenous – Initially, 50-100 mcg/kg
Frequency: at 1-2 minute intervals
Note: if necessary, may increase dose by 50-100 mcg/kg increments or until arrhythmia is controlled; Maximum dose: 300 mcg/kg.
Indication: Paroxysmal supraventricular tachycardia
Age: Child
Dose: Intravenous – Initially, 50-100 mcg/kg
Frequency: at 1-2 minute intervals
Note: if necessary, may increase dose by 50-100 mcg/kg increments or until arrhythmia is controlled; Maximum dose: 300 mcg/kg.
Administration
  • For hospital use only
  • Given by IV injection
Side Effect

Drug Interaction
Drug NameRisk Factors
Methylxanthines (caffeine, theophylline)
Antagonize adenosine effects
Carbamazepine
May increase the risk of heart block

Disease Interaction
Disease NameRisk Factors
2nd or 3rd Degree AV Block
Risk of severe heart rhythm problems
Sick Sinus Syndrome
Dangerous without pacemaker

Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store in cool dry place protected from light. Keep out of reach of children. Do not refrigerate as crystallization may occur. If crystallization has occurred, dissolve crystals by warming to room temperature. The solution must be clear at the time of use.

Data Sources

Clinical & regulatory information on this page is compiled from the following government sources:

DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.